Inhibition	O
of	O
growth	O
,	O
migration	O
and	O
invasion	O
of	O
human	O
bladder	O
cancer	O
cells	O
by	O
antrocin	O
,	O
a	O
sesquiterpene	O
lactone	O
isolated	O
from	O
Antrodia	O
cinnamomea	O
,	O
and	O
its	O
molecular	O
mechanisms	O
.	O
Bladder	B-DISEASE
cancer	E-DISEASE
is	O
the	O
ninth	O
most	O
common	O
cancer	S-DISEASE
around	O
the	O
world	O
,	O
and	O
is	O
a	O
severe	O
urological	B-DISEASE
cancer	E-DISEASE
irrespective	O
of	O
sex	O
.	O


Approximately	O
65	O
%	O
of	O
the	O
bladder	B-DISEASE
cancers	E-DISEASE
will	O
recur	O
following	O
surgery	O
;	O
with	O
more	O
than	O
20	O
%	O
of	O
those	O
patients	O
showing	O
an	O
advanced	O
and	O
metastatic	O
stage	O
,	O
with	O
reducing	O
prognosis	O
.	O


Metastasis	O
causes	O
the	O
most	O
death	O
of	O
bladder	B-DISEASE
cancer	E-DISEASE
yet	O
current	O
therapeutic	O
options	O
remain	O
limited	O
.	O


Antrocin	O
,	O
a	O
sesquiterpene	O
lactone	O
isolated	O
from	O
Antrodia	O
cinnamomea	O
,	O
has	O
been	O
identified	O
as	O
a	O
strong	O
cytotoxic	O
agent	O
against	O
lung	O
and	O
metastatic	O
breast	O
cancer	S-DISEASE
cells	O
;	O
however	O
,	O
the	O
effects	O
and	O
mechanisms	O
of	O
antrocin	O
on	O
cancer	O
growth	O
and	O
metastasis	O
remain	O
largely	O
unclear	O
.	O


This	O
study	O
showed	O
that	O
treatment	O
with	O
cytotoxic	O
concentration	O
of	O
antrocin	O
induced	O
both	O
intrinsic	O
and	O
extrinsic	O
apoptotic	O
pathways	O
in	O
human	O
bladder	O
cancer	O
5637	O
cells	O
,	O
evidenced	O
by	O
increase	O
of	O
Fas	O
,	O
DR5	O
,	O
Bax	O
expression	O
and	O
caspase	O
-	O
3	O
,	O
-	O
8	O
and	O
-	O
9	O
activation	O
.	O


Exposure	O
to	O
non	O
-	O
cytotoxic	O
concentrations	O
of	O
antrocin	O
significantly	O
inhibited	O
cell	O
growth	O
,	O
migration	O
,	O
and	O
invasion	O
,	O
which	O
was	O
associated	O
with	O
decreased	O
phosphorylation	O
of	O
focal	O
adhesion	O
kinase	O
(	O
FAK	O
)	O
and	O
paxillin	O
.	O


Antrocin	O
also	O
reduced	O
subcellular	O
distribution	O
of	O
FAK	O
and	O
paxillin	O
at	O
the	O
focal	O
adhesion	O
contacts	O
of	O
the	O
cell	O
periphery	O
site	O
,	O
and	O
disrupted	O
the	O
formation	O
of	O
filopodia	O
and	O
lamellipodia	O
.	O


Moreover	O
,	O
antrocin	O
increased	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
-	O
related	O
gene	O
E	O
-	O
cadherin	O
and	O
decreased	O
vimentin	O
expression	O
.	O


Real	O
-	O
time	O
PCR	O
analysis	O
showed	O
that	O
antrocin	O
downregulated	O
the	O
expression	O
of	O
mRNA	O
of	O
several	O
MMPs	O
,	O
including	O
MMP	O
-	O
2	O
.	O


Moreover	O
,	O
the	O
phosphorylation	O
of	O
ERK	O
and	O
c	O
-	O
Fos	O
were	O
also	O
attenuated	O
by	O
antrocin	O
.	O


Data	O
from	O
chromatin	O
immunoprecipitation	O
assay	O
demonstrated	O
that	O
antrocin	O
decreased	O
the	O
DNA	O
binding	O
activity	O
of	O
c	O
-	O
Fos	O
to	O
the	O
upstream	O
/	O
enhancer	O
region	O
of	O
MMP	O
-	O
2	O
promoter	O
,	O
an	O
action	O
likely	O
to	O
result	O
in	O
the	O
reducing	O
MMP	O
-	O
2	O
expression	O
.	O


Overall	O
,	O
this	O
is	O
the	O
first	O
study	O
which	O
demonstrates	O
that	O
antrocin	O
-	O
inhibited	O
migration	O
and	O
invasion	O
of	O
bladder	O
cancer	O
cells	O
is	O
partly	O
via	O
inactivation	O
of	O
FAK	O
-	O
paxillin	O
and	O
ERK	O
-	O
c	O
-	O
Fos	O
-	O
MMP2	O
signaling	O
pathways	O
.	O


Both	O
antrocin	O
-	O
induced	O
intrinsic	O
and	O
extrinsic	O
apoptosis	O
is	O
through	O
upregulation	O
of	O
pro	O
-	O
apoptotic	O
proteins	O
,	O
including	O
Bax	O
,	O
Fas	O
,	O
and	O
DR5	O
.	O


These	O
results	O
provide	O
insights	O
for	O
understanding	O
the	O
anti	O
-	O
cancer	S-DISEASE
effects	O
and	O
mechanisms	O
of	O
antrocin	O
in	O
human	O
bladder	O
cancer	O
cells	O
and	O
indicate	O
that	O
antrocin	O
may	O
be	O
a	O
potential	O
therapeutic	O
agent	O
for	O
invasive	O
bladder	O
cancer	O
cells	O
by	O
inhibition	O
of	O
metastasis	O
and	O
induction	O
of	O
apoptosis	O
.	O
